Hypothalamic Hamartoma: Comparison of Clinical Presentation and Magnetic Resonance ImagesDebeneix C.a · Bourgeois M.b · Trivin C.c · Sainte-Rose C.b · Brauner R.a
aPediatric Endocrinology and bNeurosurgery Departments and cPhysiology Laboratory, Université René Descartes and Hôpital Necker-Enfants Malades, Assistance Publique-Hopitaux de Paris, France
Do you have an account?
- Rent for 48h to view
- Buy Cloud Access for unlimited viewing via different devices
- Synchronizing in the ReadCube Cloud
- Printing and saving restrictions apply
Rental: USD 8.50
Cloud: USD 20.00
Background/Aims: Hypothalamic hamartoma (HH) is one of the most frequent causes of organic central precocious puberty (CPP). We compared the clinical presentation and the magnetic resonance images (MRI) of 19 patients with HH aged 5.7 ± 4.1 (SD) years at the first endocrine evaluation. They had isolated CPP (group 1, n = 9), CPP plus gelastic seizures (group 2, n = 5), isolated seizures (group 3, n = 4), and 1 patient was asymptomatic. Methods/Results: All patients without neurological symptoms (group 1 and the asymptomatic patient) had pedunculated lesion (diameter 6.4 ± 3.6 (3–15) mm), suspended from the floor of the third ventricle. All patients with neurological symptoms (groups 2 and 3) had sessile lesion (diameter 18.3 ± 9.6 (10–38) mm, p = 0.0005 compared to the others), located in the interpeduncular cistern with extension to the hypothalamus. Seven patients were overweight. The growth hormone peak, free thyroxine, cortisol and prolactin concentrations, and the concomitant plasma and urinary osmolalities were normal in all the cases evaluated. The mean predicted or adult heights of 10 patients treated 5.2 ± 3.3 years for CPP with gonadotropin hormone releasing hormone (GnRH) analog were –0.3 ± 1.7 SD, similar to their target height –0.1 ± 0.9 SD. Conclusion: The clinical presentation of HH depends on its anatomy: small and pedunculated HH are associated with CPP, while large and sessile HH are associated with seizures. The hypothalamic-pituitary function in these cases is normal, which suggests that the absence of CPP is not due to gonadotropin deficiency. GnRH analog treatment preserves the growth potential in those with CPP.
© 2002 S. Karger AG, Basel
Chemaitilly W, Trivin C, Adan L, Gall V, Sainte-Rose C, Brauner R: Central precocious puberty: Clinical and laboratory features. Clin Endocrinol 2001;54:289–294.
- Pescovitz OH, Comite F, Hench K, Barnes K, McNemar A, Foster C, Kenigsberg D, Loriaux L, Cutler GB: The NIH experience with precocious puberty: Diagnostic subgroups and response to short-term luteinizing hormone-releasing hormone analogue therapy. J Pediatr 1986;108:47–54.
- Judge DM, Kulin HE, Page R, Santen R, Trapukdi S: Hypothalamic hamartoma: A source of luteinizing hormone-releasing factor in precocious puberty. N Engl J Med 1977;296:7–10.
- Barral V, Brunelle F, Brauner R, Rappaport R, Lallemand D: MRI of hypothalamic hamartomas in children. Pediatr Radiol 1988;18:449–452.
Sempe M, Pedron G, Roy Pernot MP: Auxologie, méthode et séquences. Paris, Theraplix, 1979.
- Rolland-Cachera MF, Cole TJ, Sempé M, Tichet J, Rossignol C, Charraud A: Body mass index variations: Centiles from birth to 87 years. Eur J Clin Nutr 1991;45:13–21.
- Marshall WA, Tanner JM: Variations in the pattern of pubertal changes in girls. Arch Dis Child 1969;44:291–303.
- Marshall WA, Tanner JM: Variations in the pattern of pubertal changes in boys. Arch Dis Child 1970;45:13–23.
Tanner JM, Goldstein H, Whitehouse RH: Standards for children’s height at ages 2–9 years allowing for height of parents. Arch Dis Child 1970;47:755–762.
Greulich WW, Pyle SI: Radiographic Atlas of Skeletal Development of the Hand and Wrist, ed 2. Stanford, Stanford University Press, 1959.
Bayley N, Pinneau SR: Tables for predicting adult height from skeletal age: Revised for use with Greulich Pyle hand standards. J Pediatr 1952;50:432–441.
- Oerter KE, Uriarte MM, Rose SR, Barnes KM, Cutler GB Jr: Gonadotropin secretory dynamics during puberty in normal girls and boys. J Clin Endocrinol Metab 1990;71:1251–1258.
Cacciari E, Fréjaville E, Cicognani A, Pirazzoli P, Frank G, Balsamo A, Tassinari D, Zappulla F, Bergamaschi R, Cristi GF: How many cases of true precocious puberty in girls are idiopathic? J Pediatr. 1983;102:357–360.
- Arita K, Ikawa F, Kurisu K, Sumida M, Harada K, Uozumi T, Monden S, Yoshida J, Yoshikazu N: The relationship between magnetic resonance imaging findings and clinical manifestations of hypothalamic hamartoma. J Neurosurg 1999;91:212–220.
- Boyko OB, Curnes JT, Oakes WJ, Burger PC: Hamartomas of the tuber cinereum: CT, MR, and pathological findings. AJNR 1991;12:309–314.
- Harada K, Yoshida J, Wakabayashi T, Okabe H, Sugita K: A super long-acting LH-RH analogue induces regression of hypothalamic hamartoma associated with precocious puberty. Acta Neurochir 1995;137:102–105.
- Jung H, Carmel P, Schwartz MS, Witkin JW, Bentele KHP, Westphal M, Piatt JH, Costa ME, Cornea A, Ma YJ, Ojeda SR: Some hypothalamic hamartomas contain transforming growth factor α, a puberty-inducing growth factor but no luteinizing hormone-releasing hormone neurons. J Clin Endocrinol Metab 1999;84:4695–4701.
Berkovic SF, Kuzniecky RI, Andermann F: Human epileptogenesis and hypothalamic hamartomas: New lessons from an experiment of nature. Epilepsia 1997;38:1–3.
- Mahachoklertwattana P, Kaplan S, Grumbach MM: The luteinizing hormone-releasing hormone-secreting hypothalamic hamartoma is a congenital malformation: Natural history. J Clin Endocrinol Metab 1993;77:118–124.
- Feuillan PP, Jones JV, Barnes K, Oerter-Klein K, Cutler GB: Reproductive axis after discontinuation of gonadotropin-releasing hormone analog treatment of girls with precocious puberty: Long-term follow-up comparing girls with hypothalamic hamartoma to those with idiopathic precocious puberty. J Clin Endocrinol Metab 1999;84:44–49.
- Tsugu H, Fukushima T, Nagashima T, Utsunomiya H, Tomonaga M, Mitsudome A: Hypothalamic hamartoma associated with multiple congenital abnormalities. Two patients and a review of reported cases. Pediatr Neurosurg 1998;29:290–296.
- Fujiwara I, Kondo Y, Iinuma K: Oral-facial-digital syndrome with hypothalamic hamartoma, postaxial ray hypoplasia of the limbs, and vagino-cystic communication: A new variant? Am J Med Genet 1999;83:77–81.
- Zuniga OF, Tanner SM, Wild WO, Mosier HD Jr: Hamartoma of CNS associated with precocious puberty. Am J Dis Child 1983;137:127–133.
Uriarte MM, Oerter Klein K, Barnes KM, Pescovitz OH, Loriaux DL, Cutler GB: Gonadotrophin and prolactin secretory dynamics in girls with normal puberty, idiopathic precocious puberty and precocious puberty due to hypothalamic hamartoma. Clin Endocrinol 1998;49:363–368.
- Comite F, Pescovitz OH, Rieth KG, Dwyer AJ, Hench K, McNemar A, Loriaux L, Cutler GB: Luteinizing hormone-releasing hormone analog treatment of boys with hypothalamic hamartoma and true precocious puberty. J Clin Endocrinol Metab 1984;59:888–892.
- De Brito VN, Latronico AC, Arnhold IJP, Lo LSS, Domenice S, Albano MCC, Fragoso MCBV, Mendonca BB: Treatment of gonadotropin-dependent precocious puberty due to hypothalamic hamartoma with gonadotropin releasing hormone agonist depot. Arch Dis Child 1999;80:231–234.
Article / Publication Details
Copyright / Drug Dosage / DisclaimerCopyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.